Detalhe da pesquisa
1.
Benralizumab in severe eosinophilic asthma by previous biologic use and key clinical subgroups: real-world XALOC-1 programme.
Eur Respir J
; 2024 Apr 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38575162
2.
Asthma exacerbations are associated with a decline in lung function: a longitudinal population-based study.
Thorax
; 78(7): 643-652, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-35922128
3.
Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials.
Br J Dermatol
; 188(6): 740-748, 2023 05 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-36994947
4.
Adrenal function recovery after durable oral corticosteroid sparing with benralizumab in the PONENTE study.
Eur Respir J
; 60(6)2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35896216
5.
Baseline type 2 biomarker levels and response to tezepelumab in severe asthma.
Allergy
; 77(6): 1786-1796, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34913186
6.
Benralizumab improves symptoms of patients with severe, eosinophilic asthma with a diagnosis of nasal polyposis.
Allergy
; 77(1): 150-161, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33978983
7.
Patient characteristics, biomarkers and exacerbation risk in severe, uncontrolled asthma.
Eur Respir J
; 58(6)2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34112734
8.
Tezepelumab improves patient-reported outcomes in patients with severe, uncontrolled asthma in PATHWAY.
Ann Allergy Asthma Immunol
; 126(2): 187-193, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33169672
9.
SOURCE: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of tezepelumab in reducing oral corticosteroid use in adults with oral corticosteroid dependent asthma.
Respir Res
; 21(1): 264, 2020 Oct 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-33050928
10.
NAVIGATOR: a phase 3 multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma.
Respir Res
; 21(1): 266, 2020 Oct 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-33050934
11.
GOLD assessment of COPD severity in the Clinical Practice Research Datalink (CPRD).
Pharmacoepidemiol Drug Saf
; 28(2): 126-133, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29740896
12.
Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol.
Respir Res
; 18(1): 106, 2017 05 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-28558833
13.
The effect of aclidinium bromide on daily respiratory symptoms of COPD, measured using the Evaluating Respiratory Symptoms in COPD (E-RS: COPD) diary: pooled analysis of two 6-month Phase III studies.
Respir Res
; 17(1): 61, 2016 05 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-27215749
14.
Effect of Aclidinium Bromide on Exacerbations in Patients with Moderate-to-Severe COPD: A Pooled Analysis of Five Phase III, Randomized, Placebo-Controlled Studies.
COPD
; 13(6): 669-676, 2016 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-27159613
15.
Characterisation and impact of reported and unreported exacerbations: results from ATTAIN.
Eur Respir J
; 44(5): 1156-65, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25234803
16.
Aclidinium improves exercise endurance, dyspnea, lung hyperinflation, and physical activity in patients with COPD: a randomized, placebo-controlled, crossover trial.
BMC Pulm Med
; 14: 209, 2014 Dec 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-25539654
17.
Use of CompEx in eosinophilic patients with severe, uncontrolled asthma on benralizumab.
ERJ Open Res
; 10(2)2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38500798
18.
Efficacy and safety of aclidinium/formoterol versus monotherapies and aclidinium versus placebo in Chinese and other Asian patients with moderate-to-severe COPD: The AVANT Phase 3 study.
Respir Med
; 218: 107393, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37640273
19.
The Pharmacokinetics, Safety and Tolerability of Aclidinium Bromide 400 µg Administered by Inhalation as Single and Multiple (Twice Daily) Doses in Healthy Chinese Participants.
Int J Chron Obstruct Pulmon Dis
; 18: 2725-2735, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-38046981
20.
Severe Asthma Standard-of-Care Background Medication Reduction With Benralizumab: ANDHI in Practice Substudy.
J Allergy Clin Immunol Pract
; 11(6): 1759-1770.e7, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36948488